Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepoloxamer in Subjects With Renal Impairment
NCT02646358Phase 1Completed
- Sponsor
- Mast Therapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of vepoloxamer in sickle cell disease (SCD), sponsored by Mast Therapeutics, Inc. Started Jan 2016; status: completed.
02
Drugs
vepoloxamer
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02646358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646358.